Replicative and biochemical ageing features among females with primary ovarian insufficiency

BACKGROUND: One of the most dangerous reproductive pathologies is primary ovarian insufficiency (POI). Except manifestation in the age <40 years old it leads to demographical losses, decrease of chances for healthy aging. POI can be characterized as summary of secondary amenorrhea, total estrogenic deficiency and hypergonadotropic hypogonadism. Hence, POI has probably harmful effect on telomere length. Telomere length determining and sex steroid replacement therapy may be promising and effective to prevent decrease of life quality/ longevity among females with POI.

AIM: To evaluate features of replicative (telomere length) and biochemical (metabolic syndrome) markers among females with primary ovarian insufficiency.

MATERIALS AND METHODS. Research has been provided in collaboration between Endocrinology Research Centre of the Russian Ministry of Health and Lomonosov Moscow State University Medical Research and Educational Centre in the period since 10.01.2021 until 01.08.2022. Females with non-iatrogenic hypergonadotropic hypogonadism caused by primary ovarian insufficiency (n=33); healthy females of reproductive age (18–49 y.o.; n=24). Patients have undergone laboratory genetic (leucocyte telomere length), biochemical analyses. DNA extraction — with Qiagen DNA blood mini kit (Germany).

Leukocyte telomere length — with real-time polymerase chain reaction PCR (Flow-fish). Soft program IBM SPSS Statistics (version 26,0 for Windows).

RESULTS. Females with POI due to estrogenic deficiency have slightly shorter mean telomere length (10,0 [7,9–10,7] kB, than healthy females of reproductive age (10,8 [10,0–13,1] кБ, р<0,001). Females with POI due to estrogenic deficiency have higher chances for development of carbohydrate metabolism disturbances (prediabetes) (р<0,043), increasement of FSH level (р<0,001). FSH level correlates moderately and negatively (ρ=0,434) with leukocyte telomere length (р<0,001).

CONCLUSIONS. Female with POI and receiving sex steroid replacement therapy have decrease of telomere length and increase of chances for carbohydrate metabolism disturbances in opposite to healthy reproductive females.

1. Piedade KC, Spencer H, Persani L, Nelson LM. Optimizing fertility in primary ovarian insufficiency: case report and literature review. Front Genet. 2021;12. doi: https://doi.org/10.3389/fgene.2021.676262

2. Andreeva EN, Absatarova YuS, Akhmatova RR., et al. Primary ovarian insufficiency: from basis of pathogenesis to treatment perspectives. Vopr. ginekol. akus. perinatol. (Gynecology, Obstetrics and Perinatology). 2021;20(5):100-107. (In Russ.). doi: https://doi.org/10.20953/1726-1678-2021-5-100-107

3. Albright F, Smith PH, Fraser R. A syndrome characterized by primary ovarian insufficiency and decreased stature. Am J Med Sci. 1942;204(5):625-648. doi: https://doi.org/10.1097/00000441-194211000-00001

4. Liu L, Wang H, Xu G, Liu L. Tet1 deficiency leads to premature ovarian failure. Front Cell Dev Biol. 2021;9(5):625-648. doi: https://doi.org/10.3389/fcell.2021.644135

5. Szeliga A, Calik-Ksepka A, Maciejewska-Jeske M, et al. Autoimmune Diseases in Patients with Premature Ovarian Insufficiency—Our Current State of Knowledge. Int J Mol Sci. 2021;22(5):2594. doi: https://doi.org/10.3390/ijms22052594

6. Shahabi P, Asadzadeh S, Bannazadeh Baghi H, Sadeghzadeh Oskouei B. Pregnancy after mumps: a case report. J Med Case Rep. 2019;13(1):379. doi: https://doi.org/10.1186/s13256-019-2271-9

7. Wilkins J, Al-Inizi S. Premature ovarian insufficiency secondary to COVID-19 infection: An original case report. Int J Gynaecol Obstet. 2021;154(1):179-180. doi: https://doi.org/10.1002/ijgo.13719

8. Armeni E, Paschou SA, Goulis DG, Lambrinoudaki I. Hormone therapy regimens for managing the menopause and premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101561. doi: https://doi.org/10.1016/j.beem.2021.101561

9. Gurrala R, Kilanowski-Doroh IM, Hutson DD, et al. Alterations in the estrogen receptor profile of cardiovascular tissues during aging. Geroscience. 2021;43(1):433-442. doi: https://doi.org/10.1007/s11357-021-00331-3

10. Liu B, He Y, Wang Y, et al. Structure of active human telomerase with telomere shelterin protein TPP1. Nature. 2022;604(7906):578-583. doi: https://doi.org/10.1038/s41586-022-04582-8

11. Roake CM, Artandi SE. Regulation of human telomerase in homeostasis and disease. Nat Rev Mol Cell Biol. 2020;21(7):384-397. doi: https://doi.org/10.1038/s41580-020-0234-z

12. Gaydosh L, Mitchell C, Notterman D, et al. Demographic and developmental patterns in telomere length across adolescence. Biodemography Soc Biol. 2020;66(3-4):208-219. doi: https://doi.org/10.1080/19485565.2021.1983758

13. Turner K, Vasu V, Griffin D. Telomere biology and human phenotype. Cells. 2019;8(1):73. doi: https://doi.org/10.3390/cells8010073

14. Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426-446. doi: https://doi.org/10.1080/13697137.2020.1804547

15. Turner K, Vasu V, Griffin D. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-937. doi: https://doi.org/10.1093/humrep/dew027